Literature DB >> 10501881

Significant correlation between serum level of hepatocyte growth factor and progression of gastric carcinoma.

S U Han1, J H Lee, W H Kim, Y K Cho, M W Kim.   

Abstract

Hepatocyte growth factor (HGF) can promote proliferation of many types of tumor cells including gastric cancer cells. To study the role of HGF in the progression of gastric carcinoma, HGF levels were measured by an enzyme immunoassay (EIA) system in sera of gastric cancer patients and followed up the levels after the operation. The mean serum HGF level in 212 healthy control subjects, 140 patients with primary gastric cancer, and 13 patients with recurrent gastric cancer were 0.199 +/- 0.073, 0.325 +/- 0.209, and 0.578 +/- 0.258 ng/ml, respectively. The increase of the levels was significantly correlated with the progression of tumor stage. The levels decreased to normal levels 1 month after curative resection of the tumors. However, the levels did not decrease significantly in nonresected cases. During the follow-up of the patients for several months, the level was significantly increased in recurrent gastric cancer patients, whereas there was no increase in nonrecurrent patients. In conclusion, the serum HGF levels significantly correlated with the aggressiveness of the tumors, suggesting an important role of HGF in the progression of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501881     DOI: 10.1007/s002689900642

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  14 in total

1.  A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.

Authors:  Yoon-Koo Kang; Kei Muro; Min-Hee Ryu; Hirofumi Yasui; Tomohiro Nishina; Baek-Yeol Ryoo; Yukimasa Kamiya; Shiro Akinaga; Narikazu Boku
Journal:  Invest New Drugs       Date:  2013-12-15       Impact factor: 3.850

2.  Cancer Cell Derived Small Extracellular Vesicles Contribute to Recipient Cell Metastasis Through Promoting HGF/c-Met Pathway.

Authors:  Zhi Qiao; Yan Zhang; Maolin Ge; Sha Liu; Xiaoteng Jiang; Zhi Shang; Han Liu; Chengxi Cao; Hua Xiao
Journal:  Mol Cell Proteomics       Date:  2019-06-13       Impact factor: 5.911

3.  Expression of some tumor associated factors in human carcinogenesis and development of gastric carcinoma.

Authors:  Ming-Dong Zhao; Xue-Mei Hu; Dian-Jing Sun; Qun Zhang; Yu-Hao Zhang; Wei Meng
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

4.  Molecular cytogenetic evaluation of gastric cardia adenocarcinoma and precursor lesions.

Authors:  H van Dekken; J C Alers; P H Riegman; C Rosenberg; H W Tilanus; K Vissers
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

5.  Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma.

Authors:  Sang-Uk Han; Hwa-Young Lee; Jae-Ho Lee; Wook-Hwan Kim; Hyunja Nam; Hong Kim; Yong-Kwan Cho; Myung-Wook Kim; Kuhn Uk Lee
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

6.  Loss of HGF activator inhibits foveolar hyperplasia induced by oxyntic atrophy without altering gastrin levels.

Authors:  Yukinori Yamagata; Susumu Aikou; Tsuyoshi Fukushima; Hiroaki Kataoka; Yasuyuki Seto; Hiroyasu Esumi; Michio Kaminishi; James R Goldenring; Sachiyo Nomura
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-11       Impact factor: 4.052

7.  Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621.

Authors:  Neil R Michaud; Jitesh P Jani; Stephen Hillerman; Konstantinos E Tsaparikos; Elsa G Barbacci-Tobin; Elisabeth Knauth; Henry Putz; Mary Campbell; George A Karam; Boris Chrunyk; David F Gebhard; Larry L Green; Jinghai J Xu; Margaret C Dunn; Tim M Coskran; Jean-Martin Lapointe; Bruce D Cohen; Kevin G Coleman; Vahe Bedian; Patrick Vincent; Shama Kajiji; Stefan J Steyn; Gary V Borzillo; Gerrit Los
Journal:  MAbs       Date:  2012-09-24       Impact factor: 5.857

8.  Prognostic value of c-Met expression in oral squamous cell carcinoma.

Authors:  Christian Freudlsperger; Dorothea Alexander; Siegmar Reinert; Juergen Hoffmann
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

9.  Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation.

Authors:  Lihua Zhang; Wenbin Huang; Jieyu Chen; Xiaojun Zhou; Zhenfeng Lu; Hangbo Zhou
Journal:  Dig Dis Sci       Date:  2006-12-15       Impact factor: 3.487

10.  Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.

Authors:  M Zhu; R Tang; S Doshi; K S Oliner; S Dubey; Y Jiang; R C Donehower; T Iveson; E Y Loh; Y Zhang
Journal:  Br J Cancer       Date:  2015-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.